Overview

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Status:
Active, not recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The Study's Primary Objective is to evaluate the pharmacokinetics, safety (acute effects associated with infusions, and inhibitor development) and efficacy (breakthrough bleeding and control of hemorrhaging during prophylaxis) of IB1001 in previously treated pediatric subjects with hemophilia B.
Phase:
Phase 3
Details
Lead Sponsor:
Aptevo BioTherapeutics